Sanofi and Regeneron's alirocumab achieves positive Phase III results in reducing LDL

French drug major Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) have reported results of six Phase III trials demonstrating alirocumab significantly reduced low-density lipoprotein cholesterol, at the American Heart Association (AHA) meeting.

Alirocumab is an investigational fully-human monoclonal antibody that targets the protein PCSK9 protein, and is being evaluated for its potential to lower LDL-C.

All six trials, ODYSSEY LONG TERM, COMBO I, ALTERNATIVE, OPTIONS I, OPTIONS II, and HIGH FH, met their primary efficacy endpoint of a greater reduction in LDL-C at 24 weeks, against either the active comparator or placebo, including standard-of-care therapy.